Related Experiment Video
Updated: May 4, 2026

Establishment of a Modified Ferric Chloride-Induced Superior Sagittal Sinus Thrombosis
Published on: December 30, 2025
Systemic thrombolysis for cerebral venous and dural sinus thrombosis: a systematic review
L D Viegas1, E Stolz, P Canhão
1Department of Neurosciences (Neurology), Hospital de Santa Maria, University of Lisbon, Lisbon, Portugal.
Insights
Systemic thrombolysis for cerebral venous thrombosis (CVT) showed an 88% independence rate but carried bleeding risks. Efficacy remains unproven due to limited data, though outcomes mirror previous reviews.
Area of Science:
- Neurology
- Vascular Neurology
- Interventional Neurology
Background:
- Cerebral venous and dural sinus thrombosis (CVT) management often considers thrombolytics for patients worsening on anticoagulation.
- Assessing the role of systemic thrombolysis in improving outcomes for CVT is crucial.
Purpose of the Study:
- To systematically review and analyze published data on systemic thrombolysis use in CVT.
- To evaluate the efficacy and safety profile of thrombolytic therapy in CVT patients.
Main Methods:
- A comprehensive PubMed search and reference list review were conducted.
- Data from the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT) were incorporated.
- Patient outcomes were assessed using the modified Rankin Scale (mRS) at last follow-up.
Main Results:
- 16 reports involving 26 CVT patients were analyzed; no randomized trials were found.
- Urokinase was the most common agent; intracranial hemorrhage occurred in 11.5% and serious bleeding in 11.5% (2 deaths).
- 88% of patients achieved independence (mRS 0-2), with a survival rate of 92.3%.
Conclusions:
- Systemic thrombolysis in CVT resulted in high functional independence but was associated with significant bleeding risks.
- The efficacy of systemic thrombolysis for acute CVT remains uncertain due to small sample sizes and lack of control groups.
- Bleeding complications necessitate careful consideration of the risks versus benefits in clinical practice.
Background:
The use of thrombolytics is frequently considered in patients with cerebral venous and dural sinus thrombosis (CVT) who deteriorate despite anticoagulant therapy.
Purpose:
To collect all the published information about the use of systemic thrombolysis in CVT in order to assess its efficacy and safety.
Methods:
We performed a PubMed search, checked all reference lists of studies found and used data from the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Outcome was classified at the last available follow-up by the modified Rankin Scale (mRS). The cases were stratified according to variables that might influence outcome.
Results:
A total of 16 reports (26 patients, 2 from the ISCVT and 24 from the systematic review of the literature) were included. No randomized clinical trial was found. Seven patients presented with isolated intracranial hypertension syndrome (26.9%), 17 with encephalopathy (65.4%) and 2 were comatose (7.7%). The superior sagittal sinus was the one most often affected (n = 21; 80.8%), and there was thrombosis of the deep cerebral venous system in 5 patients (19.2%). Urokinase was the thrombolytic agent most frequently administered (n = 19; 73.1%), whereas streptokinase and recombinant tissue plasminogen activator were used in 2 cases each (7.7%). Intracranial hemorrhages occurred in 3 cases (11.5%). Extracranial hemorrhages occurred in 5 cases (19.2%), and overall there were 3 cases of serious bleeding (11.5%), including 2 deaths (7.7%). Partial or complete recanalization was verified in most patients (n = 16; 61.5%). The survival rate was 92.3% (24/26 patients). At the last available follow-up, 22/25 patients regained independency (mRS scores 0-2; 88%), 2/25 died (mRS score 6; 8%) and 1/25 was severely dependent (mRS scores 3-5; 4%).
Conclusions:
In all, 88% of the CVT patients treated with systemic thrombolysis regained their independency, but 2 deaths associated with intracranial hemorrhage occurred. The mortality rate and disability at the last available follow-up were similar to those found in 2 previous systematic reviews concerning the use of thrombolytics in CVT. Due to the small sample size and lack of controls, the efficacy of systemic thrombolysis in acute CVT cannot be assessed from the published information. Concerning safety, a nonnegligible proportion of bleedings was reported.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis I: Introduction
Venous Thrombosis IV: Nursing Management
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
Hemorrhagic Stroke l: Introduction

